BioSpace News Archive

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021.

First TIGIT Inhibitor Drug Is Expected To Enter The Market In Next 2 Years Says Kuick Research.

Global Bispecific Antibodies Market Offers Billion Dollars Opportunity With 3 Approved Antibodies Says Kuick Research.

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.

Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, presented a poster at the 2021 San Antonio Breast Cancer Symposium with updated results from a four-arm Phase 1b expansion study.

Junshi Biosciences (HKEX: 1877; SSE: 688180), announced today that the National Medical Products Administration (the “NMPA”) has accepted the company’s supplemental New Drug Application (“sNDA”) for toripalimab in combination with chemotherapy as the first-line treatment of patients with treatment-naive advanced or metastatic non-small cell lung cancer (“NSCLC”) with no EGFR or ALK tumor aberrations.

High adoption rate of home kits for diagnosis of HIV and increasing investment by private as well as government organizations to develop effective diagnostic techniques are factors driving growth of the HIV diagnostics market.

Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19.

Increasing R&D activities in pharmaceutical industry is driving revenue growth of the in vivo toxicology market.

Increasing prevalence of chronic diseases and growing awareness about regular body profiling are key factors expected to drive market growth.